Literature DB >> 29290740

Vancomycin Dosing and Monitoring in the Treatment of Cystic Fibrosis: Results of a National Practice Survey.

Rebecca S Pettit1, Stacy J Peters1, Erin J McDade1, Kaci Kreilein1, Radha Patel1, Kevin Epps1, Frederick Kittell1, Mariela A Duval1, Jeffery T Zobell1.   

Abstract

OBJECTIVES: Vancomycin is commonly used in patients with cystic fibrosis (CF) to treat acute pulmonary exacerbations, but few guidelines exist to help dose and monitor patients. The objective of this study was to assess vancomycin use and monitoring strategies at Cystic Fibrosis Foundation (CFF)-accredited centers in hopes of developing and implementing vancomycin dosing and monitoring standards.
METHODS: An anonymous national cross-sectional survey of pharmacists affiliated with CFF-accredited pediatric and/or adult centers was performed by using Surveymonkey.com. The survey consisted of 3 sections: (1) CF Center Demographic Information (10 questions); 2) vancomycin use in pediatric CF patients (31 questions); and 3) vancomycin use in adult CF patients (29 questions); it was administered from March 9, 2015, to April 13, 2015.
RESULTS: The survey was completed by 31/69 (45%) pharmacists and 28 (90.3%) reported using vancomycin in the pediatric population. The most common initial starting dose for pediatric patients was 15 mg/kg/dose (57.1%) and every 6 hours was the most common dosing frequency (67.9%). The most common monitoring strategy was collection of a trough concentration (92.9%) with 57.7% of pharmacist targeting a range of 15 to 20 mg/L. The most common initial starting vancomycin dose in adults with CF was 15 mg/kg/dose (61.5%), and initial frequency of every 8 hours (73.1%). The most common monitoring strategy was a trough concentration (96.2%) with 83.3% of pharmacists reporting a goal trough range of 15 to 20 mg/L.
CONCLUSIONS: The most common vancomycin dosing reported was 15 to 20 mg/kg/dose every 6 hours (pediatric) and 15 to 20 mg/kg/dose every 8 to 12 hours (adults). Serum concentrations measured to meet monitoring parameters of trough concentrations of 15 to 20 mg/L, or area under the curve to minimum inhibitory concentration ratio > 400, were the same in both pediatric and adult patients.

Entities:  

Keywords:  antibiotics; cystic fibrosis; pediatrics; pharmacokinetics; vancomycin

Year:  2017        PMID: 29290740      PMCID: PMC5736252          DOI: 10.5863/1551-6776-22.6.406

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  14 in total

1.  Pharmacokinetics of vancomycin in adult cystic fibrosis patients.

Authors:  R A Pleasants; E L Michalets; D M Williams; W M Samuelson; J R Rehm; M R Knowles
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

2.  Utilization of antibiotics for methicillin-resistant Staphylococcus aureus infection in cystic fibrosis.

Authors:  Jeffery T Zobell; Kevin L Epps; David C Young; Madison Montague; Jared Olson; Krow Ampofo; Melissa J Chin; Bruce C Marshall; Elliott Dasenbrook
Journal:  Pediatr Pulmonol       Date:  2015-01-05

3.  National survey of extended-interval aminoglycoside dosing in pediatric cystic fibrosis pulmonary exacerbations.

Authors:  William A Prescott
Journal:  J Pediatr Pharmacol Ther       Date:  2011-10

4.  A survey of the utilization of anti-pseudomonal beta-lactam therapy in cystic fibrosis patients.

Authors:  Jeffery T Zobell; David C Young; C Dustin Waters; Krow Ampofo; Jared Cash; Bruce C Marshall; Jared Olson; Barbara A Chatfield
Journal:  Pediatr Pulmonol       Date:  2011-04-25

5.  Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.

Authors:  Patrick A Flume; Brian P O'Sullivan; Karen A Robinson; Christopher H Goss; Peter J Mogayzel; Donna Beth Willey-Courand; Janet Bujan; Jonathan Finder; Mary Lester; Lynne Quittell; Randall Rosenblatt; Robert L Vender; Leslie Hazle; Kathy Sabadosa; Bruce Marshall
Journal:  Am J Respir Crit Care Med       Date:  2007-08-29       Impact factor: 21.405

Review 6.  Pathophysiology and management of pulmonary infections in cystic fibrosis.

Authors:  Ronald L Gibson; Jane L Burns; Bonnie W Ramsey
Journal:  Am J Respir Crit Care Med       Date:  2003-10-15       Impact factor: 21.405

7.  Tobramycin and Beta-Lactam Antibiotic Use in Cystic Fibrosis Exacerbations: A Pharmacist Approach.

Authors:  Jeffery T Zobell; Kevin Epps; Frederick Kittell; Clarissa Sema; Erin J McDade; Stacy J Peters; Mariela A Duval; Rebecca S Pettit
Journal:  J Pediatr Pharmacol Ther       Date:  2016 May-Jun

Review 8.  Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections.

Authors:  James F Chmiel; Timothy R Aksamit; Sanjay H Chotirmall; Elliott C Dasenbrook; J Stuart Elborn; John J LiPuma; Sarath C Ranganathan; Valerie J Waters; Felix A Ratjen
Journal:  Ann Am Thorac Soc       Date:  2014-09

9.  A survey of once-daily dosage tobramycin therapy in patients with cystic fibrosis.

Authors:  Daniel J Van Meter; Michele Corriveau; John W Ahern; Thomas Lahiri
Journal:  Pediatr Pulmonol       Date:  2009-04

Review 10.  Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations.

Authors:  Patrick A Flume; Peter J Mogayzel; Karen A Robinson; Christopher H Goss; Randall L Rosenblatt; Robert J Kuhn; Bruce C Marshall
Journal:  Am J Respir Crit Care Med       Date:  2009-09-03       Impact factor: 21.405

View more
  1 in total

Review 1.  Mechanisms of antimicrobial-induced nephrotoxicity in children.

Authors:  Kevin J Downes; Molly Hayes; Julie C Fitzgerald; Gwendolyn M Pais; Jiajun Liu; Nicole R Zane; Stuart L Goldstein; Marc H Scheetz; Athena F Zuppa
Journal:  J Antimicrob Chemother       Date:  2020-01-01       Impact factor: 5.790

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.